MultiCell Technologies updates research results

WOONSOCKET – MultiCell Technologies announced on Aug. 10 its updates on preclinical research results for MCT-465 and MCT-485, the first of a family of prospective cancer therapeutics based on the use of its patented signaling technology. MCT-465 and MCT-485 are being investigated as prospective treatments for primary liver cancer and triple-negative breast cancer. More

This item is available in full to subscribers. If you are a current subscriber, log in to continue.

Otherwise, purchase a subscription to continue.

You can also purchase this single article, if you prefer. Click here to continue.